← Volver a la portada
Asia · Actualidad general · India Today

A cancer vaccine made for one patient? What Hyderabad's RNA Foundry is building

Publicado por India Today · India hace 8 h
A cancer vaccine made for one patient? What Hyderabad's RNA Foundry is building
India Today

Resumen detallado

Hyderabad-based biotech company PopVax has opened an RNA Foundry to develop personalised mRNA cancer vaccines using a patient's tumour genetics. While the technology offers promise, experts say questions around clinical evidence, safety, cost and accessibility remain.

What if a cancer vaccine could be designed specifically for your tumour, rather than being developed for a large group of patients? This is the idea behind personalised cancer vaccines, an emerging area of cancer research that could change how doctors approach treatment.

Hyderabad-based biotechnology company PopVax is attempting to bring this approach closer to reality through its RNA Foundry, a research, development and manufacturing facility launched in October 2026. The facility aims to design and manufacture personalised mRNA cancer vaccines based on the genetic characteristics of an individual patient's tumour.

Unlike conventional vaccines, which are generally developed for broader populations, personalised cancer vaccines are designed using the mutations found in an individual's cancer cells. The idea is to help the immune system recognise these abnormal markers and mount a targeted response against cancer cells carrying them.

However, while the development marks an interesting step for India's biotechnology sector, the science is still evolving. These vaccines remain experimental, and their effectiveness needs to be established through clinical trials.

Cancer develops when cells acquire genetic changes that allow them to grow and multiply abnormally. Some of these changes produce unusual proteins or protein fragments called neoantigens, which can help distinguish cancer cells from healthy cells.

Personalised cancer vaccines use information from a patient's tumour to identify these potential targets.

In the case of mRNA vaccines, scientists design genetic instructions that tell the body's cells to produce selected tumour-associated targets. The immune system can then learn to recognise these targets and activate immune cells, particularly T-cells, to attack cancer cells displaying them.

Explaining the science, Dr Rahul Thakur, Consultant Radiation Oncologist, TGH ONCO LIFE Cancer Centre, Talegaon, said personalised cancer vaccines are being developed using the…

"The…

Inicio del artículo, extracto de India Today. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en India Today Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.indiatoday.in)

También te puede interesar